ALKERMES, INC. for ALKERMES, INC.
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Maintain six protected classes for depression and schizophrenia under Medicare Part D
| Lobbyist | Covered position, as disclosed |
|---|---|
| ABIGAIL PINKELE | — |
Pharmacy PHA
Public law #114-198, 21st Century Cures Opioid Implementation Awareness of outcomes data and the need for training on all medication assisted treatment Initiatives to promote the use of relapse prevention post detoxification
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT FORMAN | — |
| MEGAN JACKSON | — |
| PETER NORMAN | — |
| ABIGAIL PINKELE | — |
Alcohol and Drug Abuse ALC
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings PL#114-198 Funding and implementation of Comprehensive Addiction and Recovery Act H.R. 6157 - Appropriations for DOD, Labor/HHS/Education and Continuing Appropriations for all other agencies H.R. 5895 - The Energy and Water Development and Related Agencies Appropriations Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT FORMAN | — |
| MEGAN JACKSON | — |
| PETER NORMAN | — |
| ABIGAIL PINKELE | — |
Health Issues HCR
Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments HR 5327 - Comprehensive Opioid Recovery Centers Act of 2018 S. 2589 - Comprehensive Opioid Recovery Centers Act of 2018 HR 6 - SUPPORT for Patient and Communities Act S. 2680 - the Opioid Crisis Response Act of 2018
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT FORMAN | — |
| MEGAN JACKSON | — |
| PETER NORMAN | — |
| ABIGAIL PINKELE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.